March has been an incredible month for CervoMed Inc. (CRVO), with its share price skyrocketing by 350%.
This clinical-stage company is focused on developing treatments for age-related neurologic disorders and its lead asset is Neflamapimod, a specific inhibitor of an enzyme called p38 alpha kinase, which is involved in inflammation and cellular stress responses.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.